Topical Tacrolimus for Lichen Sclerosus: Systematic Review of Efficacy and Safety

Bhagyshree Patel; Ayesha  Lala; Roberto Verdolini

doi:10.5826/dpc.1601a6957

Topical Tacrolimus for Lichen Sclerosus: Systematic Review of Efficacy and Safety

Authors

Bhagyshree Patel St Peter’s Hospital, Chertsey, Surrey, United Kingdom
Ayesha Lala St Peter’s Hospital, Chertsey, Surrey, United Kingdom
Roberto Verdolini St Peter’s Hospital, Chertsey, Surrey, United Kingdom

Keywords:

Lichen sclerosus, Topical tacrolimus, Efficacy, Safety, Calcineurin inhibitors

Abstract

Introduction: Lichen sclerosus (LS) is a chronic inflammatory dermatosis affecting both genital and extragenital sites, with a prevalence of approximately 3% among females in the United Kingdom, particularly in the post-menopausal population. Although its etiology remains incompletely understood, LS can significantly impair quality of life through pain, pruritus, and scarring [1]. Current guidelines recommend potent topical corticosteroids, most commonly clobetasol, as first-line therapy [2]; however, long-term use is limited by adverse effects such as skin atrophy [3].

Objectives: This systematic review evaluates the efficacy and safety of topical tacrolimus in the management of lichen sclerosus.

Methods: A comprehensive literature search was conducted in accordance with PRISMA guidelines [4]. Fourteen randomized controlled trials comprising 335 patients with lichen sclerosus were included.

Results: Of the included patients, 2% (N=6) presented with extragenital disease and 98% (N=331) with anogenital involvement. Most patients (81%, N=272) were treated with topical tacrolimus 0.1% twice daily, while 19% (N=63) received clobetasol as a comparator. Clinical improvement, ranging from partial symptom relief to complete remission, was observed in 90% (N=244) of tacrolimus-treated patients. Severe adverse events requiring discontinuation were rare (1%, N=3). Compared with corticosteroids, tacrolimus was associated with superior patient-reported outcomes, clinician-reported improvement, and histological response.

Conclusion: Topical tacrolimus appears to be a safe and effective therapeutic option for lichen sclerosus, demonstrating favorable clinical and histological outcomes with minimal adverse effects. Further long-term prospective trials are needed to confirm its comparative efficacy, safety, and role in future treatment guidelines.

References

Rees S, Arnold S, Parsons H, Hillman S. Vulval lichen sclerosus in UK general practice: a cross-sectional survey of patient experience. BMJ Open. 2025;15(9):e103415. DOI: 10.1136/bmjopen-2025-103415.

Clinical Effectiveness Group, British Association for Sexual Health and HIV. 2014 UK national guideline on the management of vulval conditions. London: BASHH; 2014. Available from: https://bssvd.org/wp-content/uploads/2018/06/BASH-UK-national-guideline-for-the-management-of-vulval-conditions-2014.pdf.

Niculet E, Bobeica C, Tatu AL. Glucocorticoid-induced skin atrophy: the old and the new. Clin Cosmet Investig Dermatol. 2020;13:1041–1050. DOI: 10.2147/CCID.S224211. PMID: 33116939.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71. PMID: 33782057.

Kauppila S, Kotila V, Knuuti E, Väre PO, Vittaniemi P, Nissi R. The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus. Am J Obstet Gynecol. 2009;202(2):181.e1–6. DOI: 10.1016/j.ajog.2009.09.030. PMID: 19939361.

Burrows LJ, Creasey A, Goldstein AT. The treatment of vulvar lichen sclerosus and female sexual dysfunction. J Sex Med. 2011;8(1):219–222. DOI: 10.1111/j.1743-6109.2010.02077.x. PMID: 20840539.

Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64(6):e99–e104. DOI: 10.1016/j.jaad.2010.06.011. PMID: 21571107.

Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. J Dermatol. 2012;39(2):145–150. DOI: 10.1111/j.1346-8138.2011.01384.x. PMID: 21980908.

Luesley DM, Downey G. Topical tacrolimus in the management of lichen sclerosus. BJOG. 2006;113(7):832–834. DOI: 10.1111/j.1471-0528.2006.00977.x. PMID: 16709215.

Kyriakou A, Patsialas C, Patsatsi A, Sotiriadis D. Treatment of male genital lichen sclerosus with clobetasol propionate and maintenance with either methylprednisolone aceponate or tacrolimus: a retrospective study. J Dermatolog Treat. 2013;24(6):431–434. DOI: 10.3109/09546634.2013.782385. PMID: 23530870.

Patsatsi A, Kyriakou A, Vavilis D, Mantas A, Patsialas C, Sotiriadis D. A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study. J Dermatolog Treat. 2013;24(5):336–339. DOI: 10.3109/09546634.2012.751086. PMID: 23249164.

Virgili A, Lauriola MM, Mantovani L, Corazza M. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol. 2007;87(1):69–72. DOI: 10.2340/00015555-0171. PMID: 17225013.

Nissi R, Eriksen H, Risteli J, Niemimaa M. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest. 2006;63(3):151–154. DOI: 10.1159/000096736. PMID: 17106105.

Böhm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139(7):922–924. DOI: 10.1001/archderm.139.7.922. PMID: 12873885.

Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014;71(1):84–91. DOI: 10.1016/j.jaad.2014.02.019. PMID: 24725464.

Ozer Arican G, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol. 2004;31(12):1014–1017. DOI: 10.1111/j.1346-8138.2004.tb00646.x. PMID: 15648464.

Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol. 2006;155(5):1021–1028. DOI: 10.1111/j.1365-2133.2006.07446.x. PMID: 17034536.

Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med. 2004;49(10):778–780. PMID: 15568398.

National Institute for Health and Care Excellence (NICE). BNF: Clobetasone butyrate. Available from: https://bnf.nice.org.uk/drugs/clobetasone-butyrate/. Accessed Sept 19, 2025.

Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol. 2003;149(5):960–967. DOI: 10.1111/j.1365-2133.2003.05735.x. PMID: 14616370.

Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6(12):837–847. DOI: 10.1016/S2352-4642(22)00283-8. PMID: 36306805.